Literature DB >> 19896399

Sex cord tumor with annular tubules in a young adolescent with Von Willebrand's disease.

Jennifer L Bercaw1, Judith Sanchez, Robert H Byrd, Meenakshi B Bhattacharjee, Jennifer E Dietrich.   

Abstract

BACKGROUND: Ovarian sex cord tumor with annular tubules (SCTAT) is a rare form of ovarian neoplasm. CASE: A 12-year-old female presented with menometrorrhagia. During her evaluation, she was both diagnosed with von Willebrand disease (VWD) and found to have an ovarian neoplasm, which was ultimately determined to be an ovarian sex cord tumor with annular tubules (SCTAT). SUMMARY AND
CONCLUSION: As her diagnosis was temporally associated with her worsening symptoms and the presence of an ovarian mass, this tumor may have played a role in her VWD diagnosis. There are no previously reported cases of SCTAT associated with VWD. This case reminds physicians of the importance of evaluating patients with menometrorrhagia for bleeding conditions, in addition to considering hormone-secreting ovarian neoplasms, including SCTAT. Copyright 2010 North American Society for Pediatric and Adolescent Gynecology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2009        PMID: 19896399     DOI: 10.1016/j.jpag.2009.09.006

Source DB:  PubMed          Journal:  J Pediatr Adolesc Gynecol        ISSN: 1083-3188            Impact factor:   1.814


  3 in total

Review 1.  Imaging of pediatric ovarian neoplasms.

Authors:  Monica Epelman; Kudakwashe R Chikwava; Nancy Chauvin; Sabah Servaes
Journal:  Pediatr Radiol       Date:  2011-05-13

2.  Management and prognosis of patients with ovarian sex cord tumor with annular tubules: a retrospective study.

Authors:  Qiuhong Qian; Yan You; Jiaxin Yang; Dongyan Cao; Zhaohui Zhu; Ming Wu; Jie Chen; Jinghe Lang; Keng Shen
Journal:  BMC Cancer       Date:  2015-04-12       Impact factor: 4.430

3.  A recurrence of advanced malignant sex cord tumor with annular tubules: case report.

Authors:  Ping Zheng; Jinhua Leng; Jinghe Lang
Journal:  Transl Cancer Res       Date:  2020-03       Impact factor: 1.241

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.